v3.26.1
Schedule of Financial Data for the Company’s Reportable Segment (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Segment Reporting [Line Items]    
Research & development expense $ 778 $ 916
Total operating costs and expenses 3,656 3,616
Operating loss (3,656) (3,616)
Other Expenses:    
Other expense (290) (969)
Loss on investment (68)
Interest Income 8
Interest expense, net (49) (176)
Total other expense, net (407) (1,137)
Net loss (4,063) (4,753)
Clinical Asset Development [Member]    
Segment Reporting [Line Items]    
Research & development expense 262 189
Related Parties [Member]    
Segment Reporting [Line Items]    
Research & development expense 516 727
Legal and Professional Fees [Member]    
Segment Reporting [Line Items]    
General and administrative expenses 713 760
Accounting and Audit Fees [Member]    
Segment Reporting [Line Items]    
General and administrative expenses 709 544
Salaries Payroll and Stock Based Compensation [Member]    
Segment Reporting [Line Items]    
General and administrative expenses 543 693
Other [Member]    
Segment Reporting [Line Items]    
General and administrative expenses $ 913 $ 703